Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma

Brief description of study

The primary purpose is to determine the effectiveness and tolerability of eliminating therapy as the initial approach for infants <12 months of age and <18 months of age with small I NRG Stage L 1 neuroblastoma and localized neuroblastoma. We want to know if modification of therapy will produce favorable treatment outcomes. The goal of the study is to treat non-high-risk neuroblastoma (NBL} by either not doing surgery or by changing the amount of chemotherapy given.

Clinical Study Identifier: s18-01776
ClinicalTrials.gov Identifier: NCT02176967
Principal Investigator: Chana Glasser.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.